Relevant bibliographies by topics / Alzheimer's

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Alzheimer's'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Alzheimer's.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Alzheimer's"

1

Rajesh, Ravula, Singadi Akhil Reddy, Gandikota Varma Devraj, Raghuram Bhukya, Harika Dasari, and Naaram Srichandana. "Region-based Convolutional Neural Network Driven Alzheimer’s Severity Prediction." International Journal on Recent and Innovation Trends in Computing and Communication 11, no. 6 (August 8, 2023): 465–70. http://dx.doi.org/10.17762/ijritcc.v11i6.7784.

Full text
Abstract:
It's important to note that Alzheimer's disease can also affect individuals over the age of 60, and in fact, the risk of developing Alzheimer's increases with age. Additionally, while deep learning approaches have shown promising results in detecting Alzheimer's disease, they are not the only techniques available for diagnosis and treatment. That being said, using Region-based Convolutional Neural Network (RCNN) for efficient feature extraction and classification can be a valuable tool in detecting Alzheimer's disease. This new approach to identifying Alzheimer's disease could lead to a more accurate and personalized diagnosis. It can also help in early treatment and intervention. However, it's still important to continue developing new methods and techniques for this disorder. Considering this our work proposes an innovative Region-based Convolutional Neural Network Driven Alzheimer’s Severity Prediction approach in this paper. The exhaustive experimental result carried out, which proves the efficacy of our Alzheimer prediction system.
APA, Harvard, Vancouver, ISO, and other styles
2

Corriveau, Roderick A., Walter J. Koroshetz, Jordan T. Gladman, Sophia Jeon, Debra Babcock, David A. Bennett, S. Thomas Carmichael, et al. "Alzheimer's Disease–Related Dementias Summit 2016: National research priorities." Neurology 89, no. 23 (November 8, 2017): 2381–91. http://dx.doi.org/10.1212/wnl.0000000000004717.

Full text
Abstract:
Goal 1 of the National Plan to Address Alzheimer’s Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease–related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease–Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixed-etiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.
APA, Harvard, Vancouver, ISO, and other styles
3

VanDongen, Antonius M. "Arc: A new target for treating alzheimer's disease." Open Access Government 43, no. 1 (July 8, 2024): 160–61. http://dx.doi.org/10.56367/oag-043-11454.

Full text
Abstract:
Arc: A new target for treating alzheimer's disease Antonius M. VanDongen, Associate Professor from Duke University, walks us through Arc, a new target for treating Alzheimer’s disease. Alois Alzheimer is a German psychiatrist credited with identifying the first case of the debilitating disease named after him. In 1906, he described neurofibrillary tangles and amyloid plaques in his patient’s brain as unique hallmarks of her dementia. Advances in neuroimaging, genetics, and molecular biology have expanded our understanding of the mechanisms underlying Alzheimer’s disease (AD) significantly. But despite heroic efforts to find a cure, there is currently no therapy that prevents, stabilizes or reverses the progression of this disorder that is poised to take on epidemic proportions as the world ages.
APA, Harvard, Vancouver, ISO, and other styles
4

Gemiralda, Rika Mutiara, Marlaokta Marlaokta, and Marlaokta Marlaokta. "Efek Neuroprotektor Kunyit pada Pasien Alzheimer." Jurnal Ilmu Keperawatan Jiwa 2, no. 3 (November 30, 2019): 171. http://dx.doi.org/10.32584/jikj.v2i3.431.

Full text
Abstract:
Alzheimer merupakan penyakit neurogeneratif kronis progresif. Penyakit ini ditandai dengan gangguan fungsi luhur seperti bahasa, kalkulasi, kapasitas belajar dan sulit mengambil keputusan. ‘Pikun’ merupakan istilah yang digunakan masyarakat untuk menggambarkan penyakit ini. Kehilangan memori jangka pendek merupakan kekhasan dari penyakit ini yang menyebabkan penurunkan produktivitas. Alzheimer sering terjadi pada usia > 65 tahun dan juga ditemukan pada sekitar usia 40 tahun. Kunyit (Curcuma longa L.) merupakan tanaman yang berfungsi sebagai neuroprotektor karena dapat menghambat Protein Tau, akivitas asetilkolinesterase dan berfungsi sebagai anti agregasi Aβ dan β secretase inhibitor. Literature review ini bertujuan untuk menjelaskan gambaran efek neuroprotektor pada kunyit terhadap pasien Alzheimer yang sudah dilakukan oleh peneliti sebelumnya. Metode yang digunakan dalam artikel ini adalah penelusuran artikel melalui database NCBI dan Google Scholar. Tahun penerbitan sumber pustaka adalah dari tahun 2001 sampai 2019 dengan 32 sumber pustaka.Tema dalam artikel yang dikumpulkan yaitu terkait gambaran efek neuroprotektor kunyit terhadap pasien Alzheimer. Hasil dari sintesa artikel yang telah ditemukan yaitu kunyit dapat mencegah penurunan kognitif pada pasien Alzheimer. Kata kunci : Alzheimer, Kunyit, Neuroprotektor EFFECT OF NEUROPROTECTOR TURMERIC ON ALZHEIMER’S PATIENTS ABSTRACT Alzheimer's is a chronic progressive neurogenerative disease. This disease is characterized by impaired noble functions such as language, calculations, learning capacity and difficulty making decisions. ‘Pikun’ is a word used by the community to describe this disease. Short-term memory loss is a spesific sign in the patient, this disease causes decrease in productivity. Alzheimer's often occurs at age> 65 years and is also found at around the age of 40 years. Turmeric (Curcuma longa L.) is a plant that functions as a neuroprotector because it can inhibit Tau Proteins, acetylcholinesterase activity and function as anti-aggregation Aβ and β secretase inhibitors. This literature review aims to explain the description of the effects of neuroprotector on turmeric on Alzheimer's patients that have been done by previous researchers. The method used in this article is the search of articles through the NCBI and Google Scholar databases. The themes in the articles collected are related to the description of the effects of turmeric neuroprotector on Alzheimer's patients. The year of publication of library sources is from 2001 to 2019 with 32 library sources. The results of various articles included in this article are turmeric can prevent cognitive decline in Alzheimer's patients. Keywords: Alzheimer's,Turmeric, neuroprotector
APA, Harvard, Vancouver, ISO, and other styles
5

Zarrouk, Amira, Meryam Debbabi, Maryem Bezine, El Mostafa Karym, Asmaa Badreddine, Olivier Rouaud, Thibault Moreau, et al. "Lipid Biomarkers in Alzheimer's Disease." Current Alzheimer Research 15, no. 4 (February 22, 2018): 303–12. http://dx.doi.org/10.2174/1567205014666170505101426.

Full text
Abstract:
Background: There are now significant evidences that lipid metabolism is affected in numerous neurodegenerative diseases including Alzheimer’s disease. These dysfunctions lead to abnormal levels of certain lipids in the brain, cerebrospinal fluid and plasma. It is consequently of interest to establish lipid profiles in neurodegenerative diseases. This approach, which can contribute to identify lipid biomarkers of Alzheimers' disease, can also permit to identify new therapeutic targets. It was therefore of interest to focus on central and peripheral biomarkers in Alzheimer's disease. Methods: A review of the literature on 148 papers was conducted. Based on this literature, the involvement of lipids (cholesterol and oxysterols, fatty acids, phospholipids) in Alzheimer's disease has been proposed. Results: Of the 148 references cited for lipid biomarkers for Alzheimer's disease, 65 refer to cholesterol and oxysterols, 35 to fatty acids and 40 to phospholipids. Among these lipids, some of them such as 24S-hydroxyckolesterol, open up new therapeutic perspectives in gene therapy, in particular. The results on the very long-chain fatty acids suggest the potential of peroxisomal dysfunctions in Alzheimer's disease. As for the phospholipids, they could constitute interesting biomarkers for detecting the disease at the prodromal stage. Conclusion: There are now several lines of evidence that lipids play fundamental roles in the pathogenesis of AD and that some of them have a prognostic and diagnosis value. This may pave the way for the identification of new therapeutic targets, new effective drugs and / or new treatments.
APA, Harvard, Vancouver, ISO, and other styles
6

Samborska, Julia, Paweł Więckowiak, Karina Stelmaszak, Katarzyna Stencel, Aleksandra Ogiegło-Kowalczyk, Monika Wojtasik, Michał Głodzik, Marek Miśkiewicz, Katarzyna Żak, and Martyna Łęcka. "The impact of the ketogenic diet on the health of patients with Alzheimer’s disease." Journal of Education, Health and Sport 52 (January 11, 2024): 98–110. http://dx.doi.org/10.12775/jehs.2024.52.007.

Full text
Abstract:
INTRODUCTION: Diet is an integral element of every individual's health. Its impact on the functioning of the human body has fascinated scientists for years. One of the diets that alters the mechanism of the body's functioning is the ketogenic diet. The impact of the ketogenic diet on various disorders is still under investigation. It is known to have shown numerous benefits in reducing epileptic seizures, but its impact on other neurological disorders is less known. In this literature review, the efficacy of ketogenic therapies was assessed in Alzheimer's disease. AIM OF STUDY: Review of the current literature (since 2018) on the effects of implementing a ketogenic diet in patients with Alzheimer's disease. MATERIALS AND METHODS: The review was based on data gathered from the PubMed database using the keywords: 'ketogenic diet in Alzheimer’s disease,' 'ketogenic therapies Alzheimer disease,' and 'ketogenic diet in neurological disease’. SUMMARY: The ketogenic diet enhances the daily functioning of Alzheimer's patients. It significantly improves their cognitive functions, and changes in brain blood flow are visible in imaging studies. The ketogenic diet also positively modulates the gut microbiome in Alzheimer's patients. It represents a promising option in combating cognitive symptoms of Alzheimer's disease.
APA, Harvard, Vancouver, ISO, and other styles
7

Ruzny, Fathima Aamina, Muhammed Ifham Mohamed Imtiyas, and Abdul Raheem Rizvie. "Challenges to Alzheimer Care in Pakistan." Journal of the Pakistan Medical Association 74, no. 6 (May 24, 2024): 1214. http://dx.doi.org/10.47391/jpma.10703.

Full text
Abstract:
Madam, Alzheimer's, the prime culprit behind Dementia, is a neurodegenerative disorder that gradually erases memory and cognition, affecting daily tasks 1. Symptoms often emerge in later years, and in Pakistan, where a rising aging population and middle-income status prevail, the risk amplifies. By 2030, global dementia cases can soar to 1.3 million from 850,000 in 2015, surging to 3.6 million by 2050 without preventive action 2. Urgent attention beckons. Yet, challenges abound. With Pakistan’s depleting literacy rate currently of 58.9% in 2023, misconceptions are likely 3. Stigma, cultural norms, and language barriers shroud the path to treatment. Moreover, mental health issues like depression, an Alzheimer’s symptom, are seen as taboo, deterring help-seeking. Till date, the lack of national databases stifles research progress, and a shortage of neurologists-just less than 150 for millions of people-worsens with scarce training programs4. Private caretakers in this developing country may be limited. As this chronic Alzheimer's has no cure, high drug costs hinder adherence, while the affordability of the new "Leqembi" drug, if approved, raises concerns. Additionally, access to MRI and CT scanning equipment in Pakistan is not widespread and their procurement along with testing entail significant costs. Furthermore, government policies and funding for Alzheimer's treatment and research might be insufficient with the rising aging population. NGOs in Pakistan related to Alzheimers are very limited- “Alzheimers Pakistan” the one and only centered in just three regions across this vast country. Solutions for these challenges emerge as vibrant threads. How can we aid patients and families in Alzheimer education? Imagine engaging workshops and media partnerships with prominent figures like the UNICEF Goodwill ambassadors thereby igniting a good community-healthcare bond, and envision ‘Alzheimer homes’ for patients lacking caregivers. Besides, a national database involving stakeholders, from NGOs to healthcare providers, can not only pave the way for easy data accessibility but also to proper treatment plans and protocols. Engaging these stakeholders could also lead to initiatives for more affordable medicines. For the shortage of neurologists, medical tourism initiatives that attract foreign neurologists to work temporarily in the country, sharing their expertise and contributing to healthcare delivery can be deployed. Targeted training for healthcare professionals and collaborating with international organizations for increased research, clinical trial participation and even in machinery purchase hold a promise to resolving this issue. Conclusively, emphasizing these concerns holds utmost significance in the pursuit of discovering effective interventions for this incurable ailment.
APA, Harvard, Vancouver, ISO, and other styles
8

Sianturi, Aditya Gloria Monalisa. "Stadium, Diagnosis, dan Tatalaksana Penyakit Alzheimer." Majalah Kesehatan Indonesia 2, no. 2 (October 25, 2021): 39–44. http://dx.doi.org/10.47679/makein.202132.

Full text
Abstract:
Dementia is a general term for loss of memory that can occur along with behavioral or psychological symptoms in patients. The first cause of dementia patients is Alzheimer's disease. Alzheimer’s disease is a brain degenerative disease and the most common cause of dementia. In Alzheimer’s disease, there are three development stages, which is stage 1, stage 2, and stage 3 with different clinical symptoms at each stage. There are several clinical criteria for establishing a definitive diagnosis of Alzheimer’s disease and also support examinations have to be carried out. Until now, Alzheimer’s treatment has not been cured. Giving some pharmacotherapy only to reduce the progression of Alzheimer’s disease. Demensia merupakan hilangnya ingatan yang bisa timbul bersama dengan gejala gangguan perilaku maupun psikologis pada seseorang. Penyebab pertama penderita demensia adalah penyakit Alzheimer. Penyakit Alzheimer adalah penyakit degeneratif otak dan penyebab paling umum dari demensia. Pada penyakit Alzheimer terdapat beberapa stadium perkembangan penyakit Alzheimer yaitu stadium 1, stadium 2, dan stadium 3 dengan gejala klinik yang berbeda di setiap stadium. Terdapat beberapa kriteria klinis dalam penegakan diagnosis definitif penyakit Alzheimer serta harus dilakukan pemeriksaan penunjang. Pada tatalaksana penyakit Alzheimer hingga saat ini memang belum dapat disembuhkan, Pemberian obat-obatan hanya untuk mengurangi progresifitas penyakit Alzheimer.
APA, Harvard, Vancouver, ISO, and other styles
9

Marintan, Elita, Brian Wasita, and Adi Magna. "EFFECT OF DATE FRUIT (PHOENIX DACTYLIFERA L.) EXTRACT ON TNFα LEVELS AND BRAIN WEIGHT OF ALZHEIMER’S MODEL RATS." MNJ (Malang Neurology Journal) 8, no. 1 (January 1, 2022): 25–29. http://dx.doi.org/10.21776/ub.mnj.2022.008.01.6.

Full text
Abstract:
Background: Alzheimer's disease (AD) is a neurodegenerative disorder marked by brain inflammation resulted in structural damage and brain dysfunction. Tumor necrosis factor α (TNFα) is a cytokine that plays an important role in inflammation. Dates fruit may help to fight oxidative stress and inflammation in the brain. Objective: To determine the effect of date fruit extracts on blood TNFα levels and brain weight of alzheimer’s model rats. Methods: This research is a laboratory experimental study by post-test only with control group design using alzheimer model rats. This study used 6 treatment groups with simple randomization. Each treatment group was represented by 8 Sprague Dawley rats. The normal control group (KN) was not induced by Hcy and was not given date palm extract, the negative control group (K-) was the Alzheimer's experimental rats which was not given the date palm extract, the positive group was the Alzheimer's experimental rats which was given the Donepezil (K+). Groups P1, P2, P3 were Alzheimer's experimental rats that were given date palm extract at a dose of 200, 400,800 mg / kgBW / day. The effect of date palm extract dosage on TNFα levels and brain weight were analyzed using the One Way Anova test followed by Tukey's post hoc test. Results: The difference in TNFα levels between groups showed a significant difference (p = 0.00). Meanwhile there was no significant difference in brain weight among all groups (p > 0,05). Conclusion: Date palm extract at doses of 200, 400, 800 mg / kgBW can decrease blood TNFα levels of Alzheimer’s model rats.
APA, Harvard, Vancouver, ISO, and other styles
10

Alamri, Khairun N. H., Jimmy Posangi, and Edward Nangoy. "Perbandingan Efektivitas Penggunaan Donepezil dan Memantine Terhadap Perbaikan Fungsi Kognitif pada Penyakit Alzheimer." JURNAL BIOMEDIK (JBM) 13, no. 2 (March 29, 2021): 218. http://dx.doi.org/10.35790/jbm.13.2.2021.31950.

Full text
Abstract:
Abstract: Pharmacological therapy for Alzheimer’s disease are cholinesterase inhibitors (donepezil) and N-methyl-D-aspartate (memantine) receptor antagonists. The use of donepezil and memantine in elderly patients must be considered because they can affect the pharmacokinetic process of drugs and the effect of drugs on the body.The aim of the study was knowing the difference in the effectiveness of using Donepezil and Memantine on the improvement of cognitive function in Alzheimer's patients. This study was in the form of a literature review with data searches using three databases, namely Pubmed, ClinicalKey, Science Direct. Keywords used are Donepezil AND Cognitive .AND Alzheimer, Memantine AND Cognitive AND Alzheimer. After being selected, 12 literature was obtained based on inclusion and exclusion criteria. In this study, Donepezil and memantine are beneficial in improving cognitive function in moderate to severe Alzheimer's disease but side effects tend to be more frequent with the use of donepezil than memantine. donepezil and memantine can be combined for the treatment of Alzheimer's disease but must pay attention to the effectiveness in clinical evaluation of patients and the cost effectiveness of the combination. Conclusion: Memantine and donepezil are effective and safe to use as therapy for moderate to severe Alzheimer’s disease. Donepezil and memantine combination therapy is more effective than donepezil or memantine monotherapy.Keywords: Donepezil, Memantine, Cognitive, Alzheimer Abstrak: Terapi farmakologi untuk penyakit alzheimer adalah inhibitor kolinesterase (donepezil) dan antagonis reseptor N-metil-D-aspartat (memantine). Penggunaan donepezil dan memantine pada pasien lanjut usia harus diperhatikan karena dapat mempengaruhi proses farmakokinetik obat dan efek obat terhadap tubuh. Penelitian ini bertujuan untuk mengetahui perbedaan efektivitas penggunaan Donepezil dan Memantine terhadap peningkatan fungsi kognitif pada pasien Alzheimer. Penelitian ini berbentuk Literature Review dengan pencarian data menggunakan tiga database yaitu Pubmed, ClinicalKey, Science Direct. Kata kunci yang digunakan adalah Donepezil AND Cognitive AND Alzheimer, Memantine AND Cognitive AND Alzheimer. Setelah dipilih, diperoleh 12 literatur berdasarkan kriteria inklusi dan eksklusi. Dalam penelitian ini, Donepezil dan memantine bermanfaat dalam meningkatkan fungsi kognitif pada penyakit Alzheimer sedang hingga berat tetapi efek sampingnya cenderung lebih sering dengan penggunaan donepezil daripada memantine. donepezil dan memantine dapat digabungkan untuk pengobatan penyakit Alzheimer tetapi harus memperhatikan keefektifan dalam evaluasi klinis pasien dan efektivitas biaya dari kombinasi tersebut. Kesimpulan: Memantine dan donepezil efektif dan aman digunakan sebagai terapi penyakit Alzheimer sedang hingga berat. Terapi kombinasi donepezil dan memantine lebih efektif dibandingkan dengan monoterapi donepezil atau memantine.Kata Kunci : Donepezil, Memantine, Cognitive, Alzheimer
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Alzheimer's"

1

Russell, Teresa. "Alzheimer's disease : expressed concern for problem behaviors /." free to MU campus, to others for purchase, 1997. http://wwwlib.umi.com/cr/mo/fullcit?p1390668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Navaratnam, Dasakumar Selveraj. "Cholinesterases in Alzheimer's disease." Thesis, University of Oxford, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306734.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Newman, Tracey Anne. "Ageing and Alzheimer's disease." Thesis, University of Southampton, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.246220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Montacute, Rebecca. "Infection in Alzheimer's disease." Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/infection-in-alzheimers-disease(a69fbf77-1455-4a78-a700-54815cad926d).html.

Full text
Abstract:
Infections are a common co-morbidity in Alzheimer's disease (AD), and evidence suggests that infections can exacerbate neuroinflammation and increase cognitive decline in AD patients. In AD, immune changes are observed both in the central nervous system (CNS) and in the rest of the body. However, only a few studies have investigated immune responses to infection in AD. Here, two extensively studied infections, Toxoplasma gondii (T. gondii) and Trichuris muris (T. muris) were used to investigate infection in AD. T. gondii is a protozoan parasite which is common globally, including in the developed world where AD cases are increasing dramatically. Infection with T. gondii starts in the gut, before becoming systemic and then infecting the CNS, where the parasite forms a chronic cyst infection. In contrast, T. muris is a nematode parasite, which remains localised to the gut. Notably, T. gondii is known to alter neuroinflammation and behaviour. T. gondii forms cysts preferentially in the areas of the brain commonly affected by AD, such as the hippocampus, which therefore makes it an interesting model to study co-morbidity. AD is often associated with advanced age. As we age, our immune system declines, and an important unanswered question is whether age impacts on the immune response to infection. This is of particular significance when considering chronic infections such as T. gondii, which require immune surveillance to prevent parasite recrudescence. Therefore, the aim of this thesis was to investigate infection in AD by determining: whether the immune response to an infection is altered in AD; whether the immune response to an infection in AD differs with age; what the effects of infection are on neuroinflammation, pathology and behaviour in AD; what are the effects of chronic infection with T. gondii. Immune responses to infection were altered in both the 3xTg-AD and the APP PS1 mouse models of AD, including increased inflammation and weight loss in AD mice following infection. Although older (eleven to twelve-month-old) 3xTg-AD mice showed some alterations in cytokine responses following infection, overall there were no major difference compared to younger (five to six-month-old) animals. Additionally, infection was found to alter neuroinflammation in both 3xTg-AD and APP PS1 mice, though differently. In 3xTg-AD mice, microglia activation increased following infection with T. gondii and T. muris, showing that infection did not need to be in the brain to alter neuroinflammation. In APP PS1 mice, a decrease in microglia activation occurred after infection with T. gondii, which was accompanied by an increase in IL-1alpha production and increased amyloid beta levels in APP PS1 mice following infection. However, no changes were found in behaviour following infection with T. gondii or T. muris in AD mouse models. Finally, chronic T. gondii infection was investigated in the TgF344-AD rat, which was established as a suitable AD model with both amyloid and tau pathology in which to study chronic infection. This work adds to a growing body of literature to suggest that infections are detrimental to AD patients, and that future measures to decrease morbidity could focus on further study of infections in AD, and the development of strategies to better prevent infections in AD patients.
APA, Harvard, Vancouver, ISO, and other styles
5

Zubair, Mohammed. "Metabolomics in Alzheimer's disease." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/metabolomics-in-alzheimers-disease(0872757b-d25a-4c43-bd52-915d4cad21c6).html.

Full text
Abstract:
Metabolites are a potentially useful source of detecting and identifying disease specific biomarkers. This thesis investigates the possibility of using metabolomics applications to detect Alzheimer’s disease associated metabolite peaks in patients and to detect longitudinal changes of the disease. Serum samples and clinical data were collected from 60 healthy controls and 60 Alzheimer’s disease patients (60 at baseline and 60 at 12 month follow-up). The metabolic fingerprinting of serum samples using the FT-IR lacked discriminatory power to discriminate Alzheimer’s disease and non-disease samples due to the similar magnitude of biological and analytical variation. The metabolic profiling of serum samples using the GC-ToF-MS did not reveal any significantly altered metabolite peaks between the Alzheimer’s disease and non-disease groups. Metabolic profiling of serum samples using the UPLC-LTQ/Orbitrap-MS operated in the positive ionisation mode did not reveal any significantly altered metabolite peaks between the disease and non-disease groups. Up to twelve metabolite peaks were significantly altered in the Alzheimer’s disease baseline and follow-up samples, indicating a potential association with disease progression. Metabolic profiling of serum samples using the UPLC-LTQ/Orbitrap-MS operated in the negative ionisation mode did not reveal any significantly altered metabolite peaks between Alzheimer’s disease and non-disease groups. Three metabolite peaks were significantly altered in the Alzheimer’s disease baseline and follow-up samples, indicating a potential association with disease progression. Metabolic profiling of serum samples with the UPLC-LTQ/Orbitrap-MS may potentially be used to detect disease and disease progression associated metabolite peaks. The metabolite peaks require identification followed by a validation experiment.
APA, Harvard, Vancouver, ISO, and other styles
6

Shie, Feng-Shiun. "Cholesterol and Alzheimer's disease /." Thesis, Connect to this title online; UW restricted, 2000. http://hdl.handle.net/1773/6604.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Emilsson, Lina. "Detection of Differentially Expressed Genes in Alzheimer's Disease : Regulator of G-protein Signalling 4: A Novel Mediator of APP Processing." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5910.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ingelson, Martin. "Molecular aspects of tau proteins in Alzheimer's disease and frontotemporal dementia /." Stockholm, 2001. http://diss.kib.ki.se/2001/91-628-4904-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hynd, Matthew. "Excitotoxic neurodegeneration in Alzheimer's disease /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18145.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blom, Elin. "Genetic Studies of Alzheimer's Disease." Doctoral thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-9397.

Full text
Abstract:
Patients with Alzheimer's disease (AD) often have a family history of the disease, implicating genetics as a major risk factor. Three genes are currently known to cause familial early-onset AD (<65 years): the amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2). For the much more common late-onset disease (>65 years), only the APOE gene has repeatedly been associated to AD, where the ε4 allele increases disease risk and decreases age at onset. As APOE ε4 only explains part of the total estimated disease risk, more genes are expected to contribute to AD. This thesis has focused on the study of genetic risk factors involved in AD. In the first study, we conducted a linkage analysis of six chromosomes previously implicated in AD in a collection of affected relative pairs from Sweden, the UK and the USA. An earlier described linkage peak on chromosome 10q21 could not be replicated in the current sample, while significant linkage was demonstrated to chromosome 19q13 where the APOE gene is located. The linkage to 19q13 was further analyzed in the second study, demonstrating no significant evidence of genes other than APOE contributing to this peak. In the third study, the prevalence of APP duplications, a recently reported cause of early-onset AD, was investigated. No APP duplications were identified in 141 Swedish and Finnish early-onset AD patients, implying that this is not a common disease mechanism in the Scandinavian population. In the fourth study, genes with altered mRNA levels in the brain of a transgenic AD mouse model (tgAPP-ArcSwe) were identified using microarray analysis. Differentially expressed genes were further analyzed in AD brain. Two genes from the Wnt signaling pathway, TCF7L2 and MYC, had significantly increased mRNA levels in both transgenic mice and in AD brains, implicating cell differentiation and possibly neurogenesis in AD.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Alzheimer's"

1

1936-, Wurtman Richard J., ed. Alzheimer's disease. New York: Raven Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dempsey, Denise P. Alzheimer's disease. Washington, D.C. (101 Independence Ave., S.E., Washington 20540: Science Reference Section, Science and Technology Division, Library of Congress, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ronson, Charles E. Alzheimer's diagnosis. New York: Nova Science Publishers, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dempsey, Denise P. Alzheimer's disease. Washington, D.C: Science Reference Section, Science and Technology Division, Library of Congress, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hepburn, Kenneth. Alzheimer's. [Washington, D.C.?]: Dept. of Veterans Affairs, Veterans Health Services and Research Administration, Office of Geriatrics and Extended Care, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hepburn, Kenneth. Alzheimer's. [Washington, D.C.?]: Dept. of Veterans Affairs, Veterans Health Services and Research Administration, Office of Geriatrics and Extended Care, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hepburn, Kenneth. Alzheimer's. [Washington, D.C.?]: Dept. of Veterans Affairs, Veterans Health Services and Research Administration, Office of Geriatrics and Extended Care, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hepburn, Kenneth. Alzheimer's. [Washington, D.C.?]: Dept. of Veterans Affairs, Veterans Health Services and Research Administration, Office of Geriatrics and Extended Care, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hepburn, Kenneth. Alzheimer's. [Washington, D.C.?]: Dept. of Veterans Affairs, Veterans Health Services and Research Administration, Office of Geriatrics and Extended Care, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

United States. Veterans Health Services and Research Administration. Office of Geriatrics and Extended Care, ed. Alzheimer's. Washington, D.C.?]: Department of Veterans Affairs, Veterans Health Services and Research Administration, Office of Geriatrics and Extended Care, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Alzheimer's"

1

Ravale, Ujwala Nilesh, and Rizwana Siddiqui. "Unveiling Alzheimer's." In Intelligent Solutions for Cognitive Disorders, 305–25. IGI Global, 2024. http://dx.doi.org/10.4018/979-8-3693-1090-8.ch014.

Full text
Abstract:
Alzheimer's disease primarily affects older adults and is marked by progressive memory loss, cognitive decline, and various physiological and psychological symptoms. This neuro degenerative condition significantly impacts patients, diminishing their quality of life. Alzheimer's disease (AD) is the leading cause of dementia globally, impacting neurological health. Deep learning techniques offer a potential solution by enhancing efficiency and scalability. They enable automated and early disease diagnosis. Advances in computational power and image analysis techniques have transformed medical imaging. Magnetic resonance imaging (MRI) provides detailed brain images aiding in diagnosis. A three-dimensional MRI image of AD diseases is transformed into two-dimensional image slices. These slices are then fed into a PSP-Net neural network, which is trained to identify key features then VGG16 network analyzes regions of interest within images and distinguishes between Alzheimer patient from normal individuals and facilitating accurate classification.
APA, Harvard, Vancouver, ISO, and other styles
2

Sabat, Steven R. "Alzheimer’s Disease: Biological Aspects." In Alzheimer's Disease and Dementia. Oxford University Press, 2018. http://dx.doi.org/10.1093/wentk/9780190603106.003.0002.

Full text
Abstract:
Alzheimer’s disease (AD) was first identified by Alois Alzheimer in 1906 in his patient, Frau Auguste D. Dr. Alzheimer saw Frau D in 1901 and observed her rather striking symptoms that normally would have been described as “senile dementia.” It would have been called this...
APA, Harvard, Vancouver, ISO, and other styles
3

C R, Nagarathna, and Kusuma M. "Detection and Classification of Alzheimer’s Disease using Deep Learning Techniques." In New Frontiers in Communication and Intelligent Systems, 301–7. Soft Computing Research Society, 2021. http://dx.doi.org/10.52458/978-81-95502-00-4-31.

Full text
Abstract:
From the previous decade, the specialist utilized machine learning procedures for their examination. The goal of different applications is accomplished utilizing these methods. Alzheimer's is a physical brain disease, as of late much exploration is proceeding to foster a proficient model to analyze the beginning phases of Alzheimer's. Early detection of Alzheimer’s has been considered an interesting research as it helpful to the individual and their family to think about their future. In this paper, we tested the deep learning model for identifying and classifying the various phases of Alzheimer's. We analyzed the model for the Magnetic resonance imaging dataset received from Kaggle and achieved an accuracy of 94.74%.
APA, Harvard, Vancouver, ISO, and other styles
4

Borenstein, Amy R., and James A. Mortimer. "The “First” Case." In Alzheimer's Disease, 3–5. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00001-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Borenstein, Amy R., and James A. Mortimer. "Clinical Appearance, Progression, and Classification." In Alzheimer's Disease, 7–23. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00002-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Borenstein, Amy R., and James A. Mortimer. "Epidemiologic Definition of a Case." In Alzheimer's Disease, 25–29. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00003-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Borenstein, Amy R., and James A. Mortimer. "Neuropathology of Alzheimer’s Disease." In Alzheimer's Disease, 31–47. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00004-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Borenstein, Amy R., and James A. Mortimer. "The Threshold Model of Dementia." In Alzheimer's Disease, 49–53. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00005-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Borenstein, Amy R., and James A. Mortimer. "The Prevalence of Alzheimer’s Disease." In Alzheimer's Disease, 57–73. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00006-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Borenstein, Amy R., and James A. Mortimer. "The Incidence of Alzheimer’s Disease." In Alzheimer's Disease, 75–88. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-804538-1.00007-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Alzheimer's"

1

Costa, Pedro Araujo. "Construction of an educational manual for caregivers of elderly people with Alzheimer's disease." In IV Seven International Congress of Health. Seven Congress, 2024. http://dx.doi.org/10.56238/homeivsevenhealth-010.

Full text
Abstract:
Population aging has been occurring progressively and in Brazil there is an accelerating growth curve. According to the World Health Organization, dementia is one of the greatest public health challenges of the current generation, in which the Alzheimer's disease subtype accounts for the majority of diagnosed cases. In this context, this study aimed to describe the construction of an educational manual to support family caregivers of elderly people diagnosed with Alzheimer's disease. This is a descriptive, methodological study. Initially, a bibliographic survey was carried out on the subject in the following databases: CINAHL, SCOPUS/ Elsevier and Pubmed-Medline; using the descriptors “elderly”, “Alzheimer” and “caregiver”. The educational manual was developed on the Figma platform, structured on the basis of the aspects that emerged from the bibliographic survey, considering aspects of language, illustration and layout/design. A group of researchers specializing in the subject was selected for convenience to support the construction of the educational manual. The contents chosen for the educational manual were: What is Alzheimer's disease (AD)?; What causes Alzheimer's disease (AD); The stages of Alzheimer's disease (AD); The symptoms of Alzheimer's disease (AD); How to deal with behavioral changes in Alzheimer's disease (AD); Tips on hygiene, bathing, eating, the environment, cognitive and memory activities; Bibliographical references. The aim of this study was achieved, since the manual entitled “Caring for elderly people with Alzheimer's disease (AD)” was created by selecting content from the main sources on the subject. The limitations of this study are that the subject is not exhausted by the topics covered; however, too much content could make the educational material long and tiring, which is why it was decided to cover the main topics on the subject.
APA, Harvard, Vancouver, ISO, and other styles
2

Rumao, Priti, and Mamta Padole. "Alzheimer's Disease." In DSMLAI '21': International Conference on Data Science, Machine Learning and Artificial Intelligence. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3484824.3484886.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ricardo Castillo Salazar, David, Laura Lanzarini, Héctor Gómez Alvarado, and José Varela-Aldás. "Artificial vision system to detect the mood of an Alzheimer's patient." In 13th International Conference on Applied Human Factors and Ergonomics (AHFE 2022). AHFE International, 2022. http://dx.doi.org/10.54941/ahfe1001445.

Full text
Abstract:
Dementia is a brain disorder that affects older individuals in their ability to carry out their daily activities, such as in the case of neurological diseases. The main objective of this study is to automatically classify the mood of an Alzheimer's patient into one of the following categories: wandering, nervous, depressed, disoriented, bored or normal i.e. in Alzheimer's patients from videos obtained in nursing homes for the elderly in the canton of Ambato, Ecuador. We worked with a population of 39 people from both sexes who were diagnosed with Alzheimer's and whose ages ranged between 75 and 89 years of age. The methods used are pose detection, feature extraction, and pose classification. This was achieved with the usage of neural networks, the walk classifier, and the Levenshtein Distance metric. As a result, a sequence of moods is generated, which determine a relationship between the software and the human expert for the expected effect. It is concluded that artificial vision software allows us to recognize the mood states of the Alzheimer patients during pose changes over time.
APA, Harvard, Vancouver, ISO, and other styles
4

Nafa, Fatema, Evelyn RodriguezArgueta, Annie Dequit, and Changqing Chen. "Machine Learning GUI based For Detecting Alzheimer’s." In 8th International Conference on Artificial Intelligence and Applications (AI 2022). Academy and Industry Research Collaboration Center (AIRCC), 2022. http://dx.doi.org/10.5121/csit.2022.121813.

Full text
Abstract:
Alzheimer's disease (AD), a kind of dementia, is marked by progressive cognitive and behavioural problems that appear in middle or late life. Alzheimer's disease must be detected early in order to create more effective therapies. Dr. Alois Alzheimer was the first doctor in the medical field to notice an unusual state of change in the brains of his deceased patients with mental illness, which marked the start of Alzheimer's study. Machine learning (ML) techniques nowadays employ a variety of probabilistic and optimization strategies to allow computers to learn from vast and complex datasets. Because of the limited number of labelled data and the prevalence of outliers in the current datasets, accurate dementia prediction is extremely difficult. In this research, we propose a sustainable framework for dementia prediction based on ML techniques such as Support Vector Machine, Decision Tree, AdaBoost, Random Forest, and XGmodel. All the experiments, in this literature, were conducted under the same experimental conditions using the longitudinal MRI Dataset.
APA, Harvard, Vancouver, ISO, and other styles
5

Kroma, Assem, and Richard Lachman. "Alzheimer's Eyes Challenge." In CHI PLAY '18: The annual symposium on Computer-Human Interaction in Play. New York, NY, USA: ACM, 2018. http://dx.doi.org/10.1145/3270316.3270320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Poland, Bradley W., Panayiotis Zagouras, Snehal Naik, Eric Fauman, Karl Richter, and Robert M. Peitzsch. "Alzheimer's disease target selection." In the First ACM International Conference. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1854776.1854870.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brown, Anne, Nicholas Polys, David Bevan, and Ayat Mohammed. "Insights into Alzheimer's Disease." In XSEDE16: Diversity, Big Data, and Science at Scale. New York, NY, USA: ACM, 2016. http://dx.doi.org/10.1145/2949550.2952773.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mao, Wenlu. "Overview of Alzheimer's Disease." In ICBBE '20: 2020 7th International Conference on Biomedical and Bioinformatics Engineering. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3444884.3444900.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zender, P. Mike, and Keith A. Crutcher. "Visualizing Alzheimer's disease research." In ACM SIGGRAPH 2004 Educators program. New York, New York, USA: ACM Press, 2004. http://dx.doi.org/10.1145/1186107.1186135.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shoaip, Nora, Sherif Barakat, and Mohammed Elmogy. "Alzheimer's Disease Integrated Ontology (ADIO)." In 2019 14th International Conference on Computer Engineering and Systems (ICCES). IEEE, 2019. http://dx.doi.org/10.1109/icces48960.2019.9068176.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Alzheimer's"

1

Huedepohl, Cole. Alzheimer's Disease & Gene Therapy. Ames (Iowa): Iowa State University, May 2023. http://dx.doi.org/10.31274/cc-20240624-149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Han, Nana, Yang Fang, Guozhen Zhao, and Bo Ji. The comparative efficacy and safety of acupuncture for mild and moderate Alzheimer's disease: A systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0014.

Full text
Abstract:
Review question / Objective: According to the current randomized clinical trials (RCT) of acupuncture therapy for Alzheimer's disease (AD), to evaluate their methodology, the quality of evidence and the report are evaluated and summarize evidence of important outcomes of randomized clinical trials. We aim to provide accurate clinical decision-making for acupuncture treatment of Alzheimer's disease. Condition being studied: According to the current randomized clinical trials (RCT) of acupuncture therapy for Alzheimer's disease (AD), to evaluate their methodology, the quality of evidence and the report are evaluated and summarize evidence of important outcomes of randomized clinical trials. We aim to provide accurate clinical decision-making for acupuncture treatment of Alzheimer's disease.
APA, Harvard, Vancouver, ISO, and other styles
3

Stevens, Brianna. Retinal Changes Associated with Alzheimer's Disease. Ames (Iowa): Iowa State University, January 2020. http://dx.doi.org/10.31274/cc-20240624-1231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mehegan, Laura. Alzheimer's Disease and Dementia Awareness Poll 2018. AARP Research, June 2018. http://dx.doi.org/10.26419/res.00232.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chandra, Amitabh, Courtney Coile, and Corina Mommaerts. What Can Economics Say About Alzheimer's Disease? Cambridge, MA: National Bureau of Economic Research, August 2020. http://dx.doi.org/10.3386/w27760.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brodtmann, Amy. Preparing for a world with Alzheimer's treatment. Edited by Charis Palmer. Monash University, October 2022. http://dx.doi.org/10.54377/cfa7-0cf3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mintzer, Jacobo E., D. L. Bachman, M. Stuckey, M. Ebeling, M. T. Wagner, W. J. Evans, V. Hirth, A. Walker, R. Joglekar, and W. Faison. A State-Wide Research Network for Alzheimer's Disease. Office of Scientific and Technical Information (OSTI), March 2014. http://dx.doi.org/10.2172/1123171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mehegan, Laura. Alzheimer's Disease and Dementia Awareness Poll 2018: Infographic. AARP Research, June 2018. http://dx.doi.org/10.26419/res.00232.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fink, Howard A., Laura S. Hemmy, Eric J. Linskens, Pombie C. Silverman, Roderick MacDonald, J. Riley McCarten, Kristine M. C. Talley, et al. Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia. Agency for Healthcare Research and Quality (AHRQ), April 2020. http://dx.doi.org/10.23970/ahrqepccer223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pericak-Vance, Margaret A. Whole Exome Analysis of Early Onset Alzheimer's Disease. Fort Belvoir, VA: Defense Technical Information Center, April 2013. http://dx.doi.org/10.21236/ada602412.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Alzheimer's' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography